Key Takeaways:
- GRAL shares fell 50.55% after NHS-Galleri trial missed its primary endpoint.
- Lawsuits allege GRAIL misled investors about trial design and timeline.
- Lead plaintiff deadline is Aug. 4, 2026, in Northern California federal court.
戻る
GRAIL faces securities class action after 50% stock drop on trial failure
A securities class action lawsuit hit GRAIL Inc. after its shares plunged 50.55%, wiping out $51.32 per share when a key cancer trial failed to meet its primary endpoint.
"Investor confidence depends on receiving truthful information from the companies they invest in," Joseph E. Levi, a partner at Levi & Korsinsky, said.
The complaint, filed in the U.S. District Court for the Northern District of California, alleges GRAIL and senior executives violated securities laws by making positive statements about the NHS-Galleri trial while withholding data that suggested the three-year study design was insufficient to achieve its primary endpoint. The class period runs from May 13, 2025, to Feb. 19, 2026.
The Feb. 19 disclosure that the trial failed to show a statistically significant reduction in Stage III and IV cancers sent GRAL shares from $101.53 to $50.21 overnight. Investors have until Aug. 4 to seek lead plaintiff appointment.
GRAIL, a Menlo Park, California-based biotech spun out of Illumina in 2016, developed the Galleri test, which screens for more than 50 types of cancer through a blood sample. The company enrolled 140,000 participants in the NHS-Galleri trial in the U.K., positioning it as the centerpiece of its commercial strategy.
During the class period, management described early results as "very encouraging" and characterized the mid-2026 readout as "a great calling card" for global expansion, according to the complaint. When pressed for detailed data from the first screening round, executives declined to share specifics, citing trial integrity.
The complaint alleges those omissions concealed adverse trendlines. GRAIL attributed the trial's failure, in part, to needing "a longer follow-up time" — an admission that contradicted earlier assurances the study was powered to deliver results within three years.
Bleichmar Fonti & Auld LLP and Levi & Korsinsky LLP are among the firms representing shareholders. Both firms handle securities class actions on a contingency basis.
The lawsuit adds legal overhang to a company already facing questions about its commercial prospects. GRAIL's next catalyst will be the court's decision on lead plaintiff appointment after the Aug. 4 deadline, followed by the company's response to the allegations.
This article is for informational purposes only and does not constitute investment advice.
